Cortes JE, et al. Am. J. Hematol. (2018) cited as Ref 614 in DOI: 10.1038/s41392-020-0110-5 (Q9877)

From Wikibase.slis.ua.edu
Revision as of 22:05, 20 May 2020 by Admin (talk | contribs) (‎Created claim: Property:P93: Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: phase 2 study results, #quickstatements; #temporary_batch_1590010982689)
Jump to navigation Jump to search
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
Language Label Description Also known as
English
Cortes JE, et al. Am. J. Hematol. (2018) cited as Ref 614 in DOI: 10.1038/s41392-020-0110-5
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8

    Statements

    Cortes JE
    0 references
    0 references
    2018
    0 references
    Am. J. Hematol.
    0 references
    93
    0 references
    Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: phase 2 study results (English)
    0 references